Plasma lipid-bound sialic acid alterations in neoplastic diseases

Abstract

Plasma lipid-bound sialic acid (LSA) was assayed in normal volunteers, patients with non-malignant diseases, and a variety of cancer patients. Mean plasma LSA in 50 normal volunteers, 16 patients with non-malignant diseases, 54 breast cancer, 17 lung cancer, 15 colon cancer, 7 ovarian cancer, 5 prostate cancer, 4 leukemia, 4 gastrointestinal, 3 thyroid cancer, 3 pancreas cancer and 2 adrenal cancer patients were 17.7, 23.2, 58, 85, 56.7, 46.2, 56.7, 53.3, 31.1, 33.2 and 119.5 mg/dl, respectively. None of the normal volunteers had elevated plasma LSA values. Plasma LSA level was not significantly different in male and female volunteers. Two out of 114 different cancer patients had plasma LSA levels within normal range exhibiting 98.2% sensitivity of the assay. Plasma LSA, which is relatively simple to assay, may be used as a tumor marker in wide variety of neoplastic diseases.

Protective role of Withaferin-a on red blood cell integrity during 7,12-dimethylbenz[A]anthracene induced oral carcinogenesis

“…Neoplastic transformation of a variety of cell types is associated with changes in the composition of membrane glycoproteins (Dwivedi et al, 1990). Glycoproteins are complex proteins in which carbohydrates are linked covalently to asparagine or serine or threonine residues of polypeptides.…”

Evaluation of some tumor markers, acute phase proteins, sialic acid and lipid bound sialic acid before and after chemotherapy in stomach cancer

“…The sialic acid level in malign cell surface is related with metastasis (5). Many researchers determined that total and lipid bounded sialic acid levels increased in different cancer types (27,28). It is known that the sialic acid is necessary for cell adhesion and carries out the electrostatic impulse in thrombocyte, cancer cells and erythrocytes via the negative charge (29).…”

The Utility of Lipid-Associated Sialic Acid (LASA or LSA) as a Serum Marker for Malignancy

“…The assay may be of some value in assessing the stage and metastatic spread of the disease, since in most types of cancer (e.g. breast, colon, lung and prostate cancer) sensitivity and absolute val ues are higher in extensive disease and in patients with distant metastasis than in those with local disease [3,32,33,35,36,43], The assay may also be helpful in monitoring can cer therapy [29,32,33,37,38,40,46]. In tumor recurrence 'LASA' levels often increase before the appearance of clinical symptoms.…”

“…Using a homeostatic autoregressive time-series model, a statistically significant (p < 0.05) reference change of ±51 mg/l between two consecutive measurements was found in 88% of the healthy subjects. Munjal et al [52] found an interassay variation of less than 10% and an intraassay reproducibility of 14-16%, whereas Dwivedi et al [43] found an intraassay variation of 6%. A slight, but statistically significant increase in the mean 'LASA' concentration was found in smokers and ex-smokers, when compared to nonsmok ers [30,47], As with carcinoembryonic anti gen (CEA) this should be taken into account when using the plasma concentration of se rum 'LASA' as a cancer marker.…”

“…A cut-off level of 200 mg/l, corresponding to the mean + 2 SD, is generally accepted. There is no dif ference between normal males and females [33,43], The percentage of falsely elevated 'LASA' values in healthy volunteers ranges from 0 to 15% [3, 20, 30-33, 43. 44, 49, 51-54], The test reliability using serial measure ments was examined by Shahangian et al [55].…”